Biotech Blueprint

Katerina Roznik

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.

  1. 1D AGO

    Monarez Fired, Novo’s srRNA Deal, ImmunityBio Wows in GBM — This Week in Biotech #67

    Subscribe to Biotech Blueprint for free HERE or at biotechblueprint.com

    8 min

  2. AUG 22

    Viking Falls on Obesity Pill, Rocket’s Gene Therapy Resumes, FDA Greenlights Papzimeos — This Week in Biotech #66

    Subscribe to the Biotech Blueprint weekly newsletter for free HERE. Thanks for your support.

    4 min

  3. AUG 15

    Lilly Bets on AI, Prasad Returns, and Brinsupri Breaks Through - This Week in Biotech #65

    Get the latest biotech and pharma news for free straight in your inbox. Follow Biotech Blueprint HERE.

    6 min

  4. AUG 8

    RFK Jr. Ends mRNA Funding, Sarepta Beats Q2, and Eli Lilly Falls — This Week in Biotech #64

    Subscribe to Biotech Blueprint for free for weekly newsletters right in your inbox. Thanks for your support!

    7 min

  5. AUG 1

    FDA Shake Up, Sarepta Rebounds, and Trump Targets Drug Prices — This Week in #Biotech 63

    Subscribe to Biotech Blueprint for free HERE and visit Biotech Blueprint website for more.

    9 min

  6. JUL 29

    Sarepta, Elevidys, and the Future of AAV Gene Therapy

    Subscribe to Biotech Blueprint HERE and to Biotech Capital Compass HERE. In this episode of the Biotech Blueprint podcast, I teamed up with the Biotech Capital Compass to break down Sarepta Therapeutics’ recent safety crisis, and what the FDA’s partial green light means for Elevidys, investor confidence, and the broader AAV field. We dig into the science, regulatory dynamics, and what might come next.

    40 min

  7. JUL 25

    Sarepta’s Gene Therapy Crisis Deepens — This Week in Biotech #62

    Subscribe to Biotech Blueprint HERE.

    10 min

  8. JUL 18

    CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise

    Welcome back to Biotech Blueprint!In this week’s special episode, I teamed up with the Biotech Capital Compass to examine where gene editing stands today, scientifically, commercially, and clinically. This marks the start of a multi-part series on gene therapies, viewed through both scientific and investment lenses.Subscribe to Biotech Blueprint and Biotech Capital Compass.

    57 min
See All (22)

Ratings & Reviews

5
out of 5
2 Ratings

About

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.

Information

  • Creator
    Katerina Roznik
  • Years Active
    2K
  • Episodes
    22
  • Rating
    Clean
  • Copyright
    © Katerina Roznik
  • Show Website
    Biotech Blueprint

You Might Also Like